Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Página 1 a partir de 29 resultados
Method for treating breast cancer using adenine nucleotide translocator 2 (ANT2) siRNA or ANT2 shRNA
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
FIELD OF THE INVENTION
The present invention relates to adenine nucleotide translocator 2 (ANT2) siRNA (small interfering RNA) or ANT2 shRNA (short hairpin RNA) suppressing the expression of ANT2 gene expression and anticancer agent containing the same. Furthermore, the present invention relates to
Adenine derivative as inhibitors of HSP90 for the treatment of cancer
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. National Phase of International Patent Application No. PCT/GB2007/004216, filed on Nov. 5, 2007, which claims the benefit of priority from Great Britain Application No. 0622084.2, filed on Nov. 6, 2006. The contents of these
C-nucleoside isostere of nicotinamide adenine dinucleotide, analogs thereof and use as anti-cancer agent
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND OF THE INVENTION
Throughout this application, various publications are referenced in Arabic numerals in parentheses. Full text citations of these publications can be found at the end of the specification, immediately preceding the claims. The disclosures of these publications in their
Methods and therapeutic compositions in the treatment of advanced cancer
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation of International Application No. PCT/US03/01166 filed Jan. 16, 2003, the entire disclosure of which is incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to methods and therapeutic compositions
Uses of nicotinamide adenine dinucleotide and its derivatives for treatment of malignant and infectious diseases
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND OF THE INVENTION
NAD and NADP are naturally occurring energy sources in cells. They are important cofactors to numerous enzymatic reactions. They are also substrates for NAD(P)ases which catalytically break down these products into nicotinamide and ADP-ribose or ADP-ribose phosphate. In
Detection method for cancer cell in vitro and system using the same
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
CROSS-REFERENCE TO RELATED APPLICATION
This non-provisional application claims priority under 35 U.S.C. .sctn. 119(a) to Patent Application No. 106101309 filed in Taiwan, R.O.C. on Jan. 13, 2017, the entire contents of which are hereby incorporated by reference.
BACKGROUND
Technical Field
The
CHK2 polymorphism as a cancer marker
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of PCT/EP2010/052894, filed Mar. 8, 2010 which claims priority to European Patent No. 09154527.7, filed Mar. 6, 2009, the disclosures of which are incorporated herein by reference in their entirety.
SEQUENCE LISTING
The
Use of endogenous fluorescence to identify invading metastatic breast tumor cells
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND OF INVENTION
Biomedical imaging plays a central role in a large number of diagnostic and therapeutic procedures including visualizing external and internal anatomical and physiological structures, features, and systems; evaluating complex biological events in the body at the organ,
Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND
In 2007 it was reported that over half a million people died from cancer and more than 1.4 million new cases were diagnosed in the United States. Thus, it is important to diagnose, assess prognosis for, and monitor treatment of cancer. Improved, noninvasive diagnostic compositions and
Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention pertains to the field of ameliorating the effect of drugs on the human body. More particularly, the invention pertains to a composition and a method for treatment of the side-effects associated with the administration of cancer
Method for suppressing multiple drug resistance in cancer cells
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
FIELD OF THE INVENTION
The invention relates to pharmaceutical agents and methods for use in the treatment of cancer. More specifically, the invention relates to treatment of cancer cells with L-alanosine to inhibit de novo adenosine 5'-triphosphate (ATP) synthesis in such cancer cells. In
Adenine derivatives
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND OF THE INVENTION
The present invention relates to compounds, processes for their preparation, compositions containing them, to their use in the treatment of various disorders in particular allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma,
Cyclic amp analogues, individually and in pairs, to inhibit neoplastic cell growth
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
FIELD OF THE INVENTION
The present invention relates to phosphorothioate derivatives of cyclic AMP (cAMP) analogues and their use in the regulation of abnormal cell growth, such as that characteristic of cancer cells.
BACKGROUND OF THE INVENTION
Cyclic adenosine monophosphate (cAMP) is a naturally
Neurite outgrowth agent
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Stage application of PCT/JP2011/002319, filed Apr. 20, 2011, which claims priority from Japanese application JP 2010-154279, filed Jul. 6, 2010.
TECHNICAL FIELD
The present invention relates to a nerve axon and/or neurite
Reversible inhibitors of SAH hydrolase and uses thereof
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND OF THE INVENTION
SAH hydrolase has been an attractive target for antiviral drug design based on the observation that many viruses require 5'-capped, methylated structures on their mRNA for efficient translation of viral proteins. Yuan et al., Exp. Opin. Ther. Patents, 9: 1197 1206 (1999);
O mais completo banco de dados de ervas medicinais apoiado pela ciência
- Funciona em 55 idiomas
- Curas herbais apoiadas pela ciência
- Reconhecimento de ervas por imagem
- Mapa GPS interativo - marcar ervas no local (em breve)
- Leia publicações científicas relacionadas à sua pesquisa
- Pesquise ervas medicinais por seus efeitos
- Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes
Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas
